Protagonist Therapeutics (PTGX) Stock Forecast for 2024–2028. Sell or Buy Prediction







Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …

Protagonist Therapeutics (PTGX) Stock Forecast for 2024–2028. Sell or Buy?

Updated: April 13, 2024 (05:11)

Sector: Healthcare

The share price of Protagonist Therapeutics, Inc. (PTGX) now

Latest session on the 12th of April for
Protagonist Therapeutics, Inc. is negative
Trading Volume: 637955
Open: 27.52 /  High: 27.565 /  Low: 26.655
What analysts predict: $44.2
52-week High/Low: $33.34 / $13.72

50/200 Day Moving Average: $28.23 / $21.74

This figure corresponds to the Average Price over the previous 50/200 days. For Protagonist Therapeutics stocks, the 50-day moving average is the support level today.

For Protagonist Therapeutics stocks, the 200-day moving average is the support level today.

Are you interested in Protagonist Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Protagonist Therapeutics stock price in 2024, 2025, 2026, 2027, 2028. How much will one Protagonist Therapeutics share be worth in 2024 - 2028?

When should I take profit in Protagonist Therapeutics stock? When should I record a loss on Protagonist Therapeutics stock? What are analysts' forecasts for Protagonist Therapeutics stock? What is the future of Protagonist Therapeutics stock? We forecast Protagonist Therapeutics stock performance using neural networks based on historical data on Protagonist Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Protagonist Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Protagonist Therapeutics shares. This happens once a day.


Historical and forecast chart of Protagonist Therapeutics stock

The chart below shows the historical price of Protagonist Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Protagonist Therapeutics stock price can be found in the table below.

Long-term forecasts by years.

“Protagonist Therapeutics, Inc.” is a clinical stage biopharmaceutical company with a peptide technology platform focused on the discovery and development of new chemical entities (NECs) to meet significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. His main focus is on the development of oral peptide formulations that target biological pathways, also targeting commercially available injectable antibodies. PTG-100 is an oral peptide product of an alpha-4-beta-7 (a4b7) integrin antagonist candidate who has completed a phase I clinical trial in normal healthy volunteers (NHVs). PTH-100 is being developed for the treatment of moderate to severe ulcerative colitis (UC). PTG-200 is an oral interleukin-23 (IL-23R) receptor antagonist being developed for the treatment of moderate to severe Crohn’s disease. PTG-300 is an injectable hepcidin mimetic for the treatment of rare conditions associated with iron overload.

Protagonist Therapeutics daily forecast for a month

Date Target Pes. Opt. Vol., %
Apr 15 29.50 29.02 30.06 3.58
Apr 16 29.29 28.98 29.86 3.04
Apr 17 29.59 28.84 30.19 4.66
Apr 18 29.66 29.38 30.09 2.42
Apr 19 29.86 29.30 30.14 2.87
Apr 20 30.01 29.69 30.60 3.07
Apr 21 29.62 29.35 29.90 1.87
Apr 22 29.83 29.53 30.30 2.62
Apr 23 29.65 29.19 30.05 2.96
Apr 24 29.90 29.41 30.26 2.90
Apr 25 29.36 28.96 30.09 3.93
Apr 26 28.94 28.45 29.58 3.97
Apr 27 28.66 28.04 29.06 3.66
Apr 28 28.65 28.41 29.00 2.07
Apr 29 29.44 28.83 29.99 4.02
Apr 30 30.26 29.72 30.58 2.90
May 01 30.50 30.11 31.04 3.08
May 02 30.56 30.23 31.23 3.33
May 03 30.92 30.64 31.23 1.91
May 04 30.27 29.56 30.99 4.82
May 05 30.63 30.36 31.23 2.84
May 06 30.76 30.08 31.00 3.08
May 07 30.34 29.58 30.71 3.81
May 08 30.57 30.27 30.97 2.29
May 09 30.82 30.46 31.51 3.43
May 10 31.48 31.14 31.98 2.72
May 11 31.43 30.97 31.83 2.79
May 12 31.62 30.81 32.43 5.25
May 13 31.53 31.33 31.76 1.38
May 14 31.51 31.13 32.22 3.53

Protagonist Therapeutics Daily Price Targets


Protagonist Therapeutics Stock Forecast 04-15-2024.

Forecast target price for 04-15-2024: $29.50.
Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 3.454%.
Pessimistic target level: 29.02
Optimistic target level: 30.06

Protagonist Therapeutics Stock Forecast 04-16-2024.

Forecast target price for 04-16-2024: $29.29.
Negative dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.951%.
Pessimistic target level: 28.98
Optimistic target level: 29.86

Protagonist Therapeutics Stock Forecast 04-17-2024.

Forecast target price for 04-17-2024: $29.59.
Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 4.454%.
Pessimistic target level: 28.84
Optimistic target level: 30.19

Protagonist Therapeutics Stock Forecast 04-18-2024.

Forecast target price for 04-18-2024: $29.66.
Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.365%.
Pessimistic target level: 29.38
Optimistic target level: 30.09

Protagonist Therapeutics Stock Forecast 04-19-2024.

Forecast target price for 04-19-2024: $29.86.
Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.790%.
Pessimistic target level: 29.30
Optimistic target level: 30.14

Protagonist Therapeutics Stock Forecast 04-20-2024.

Forecast target price for 04-20-2024: $30.01.
Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.981%.
Pessimistic target level: 29.69
Optimistic target level: 30.60

PTGX (PTGX) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
May. 32.49 30.50 35.22 13.39
Jun. 33.07 30.02 35.38 15.15
Jul. 31.21 30.16 33.38 9.65
Aug. 31.81 29.25 32.99 11.34
Sep. 31.88 30.28 34.37 11.91
Oct. 35.71 33.95 36.87 7.90
Nov. 37.55 36.56 39.67 7.84
Dec. 35.97 33.17 38.69 14.28

Protagonist Therapeutics forecast for this year


Protagonist Therapeutics Stock Prediction for May 2024

An uptrend is forecast for this month with an optimal target price of $32.4885. Pessimistic: $30.50. Optimistic: $35.22


Protagonist Therapeutics Stock Prediction for Jun 2024

An uptrend is forecast for this month with an optimal target price of $33.0733. Pessimistic: $30.02. Optimistic: $35.38


Protagonist Therapeutics Stock Prediction for Jul 2024

An downtrend is forecast for this month with an optimal target price of $31.2079. Pessimistic: $30.16. Optimistic: $33.38


Protagonist Therapeutics Stock Prediction for Aug 2024

An uptrend is forecast for this month with an optimal target price of $31.8071. Pessimistic: $29.25. Optimistic: $32.99


Protagonist Therapeutics Stock Prediction for Sep 2024

An uptrend is forecast for this month with an optimal target price of $31.8835. Pessimistic: $30.28. Optimistic: $34.37


Protagonist Therapeutics Stock Prediction for Oct 2024

An uptrend is forecast for this month with an optimal target price of $35.7095. Pessimistic: $33.95. Optimistic: $36.87


Protagonist Therapeutics Stock Prediction for Nov 2024

An uptrend is forecast for this month with an optimal target price of $37.5521. Pessimistic: $36.56. Optimistic: $39.67


Protagonist Therapeutics Stock Prediction for Dec 2024

An downtrend is forecast for this month with an optimal target price of $35.9749. Pessimistic: $33.17. Optimistic: $38.69



Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 36.92 33.38 39.05 14.52
Feb 35.42 33.85 36.48 7.22
Mar 35.08 32.64 36.51 10.61
Apr 34.07 32.60 35.21 7.43
May 34.23 32.79 36.94 11.23
Jun 37.93 35.24 40.16 12.24
Jul 41.25 38.92 43.33 10.17
Aug 44.02 41.59 46.77 11.07
Sep 47.72 43.66 48.98 10.87
Oct 49.55 45.87 51.46 10.86
Nov 54.01 51.10 59.13 13.59
Dec 47.66 45.60 50.52 9.74

Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 43.89 41.52 47.20 12.05
Feb 42.83 39.90 44.22 9.76
Mar 37.74 35.25 39.10 9.85
Apr 42.14 40.01 44.67 10.42
May 40.27 38.62 42.59 9.30
Jun 38.00 36.49 40.60 10.11
Jul 38.63 37.34 40.16 7.04
Aug 35.95 33.31 38.96 14.50
Sep 37.93 35.61 40.57 12.23
Oct 37.02 34.62 40.31 14.11
Nov 37.20 35.37 39.38 10.20
Dec 36.66 34.33 39.39 12.84

Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 35.17 32.84 37.23 11.79
Feb 35.21 33.56 37.87 11.38
Mar 34.70 32.24 37.66 14.38
Apr 34.49 31.39 37.10 15.40
May 34.91 32.18 35.74 9.96
Jun 35.66 33.91 36.94 8.22
Jul 38.91 36.95 42.04 12.11
Aug 36.25 33.64 39.04 13.82
Sep 36.25 34.90 37.30 6.42
Oct 37.86 36.54 39.95 8.53
Nov 36.68 34.48 38.48 10.41
Dec 35.45 33.58 38.17 12.04

Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2028

Month Target Pes. Opt. Vol., %
Jan 33.66 32.29 34.59 6.66
Feb 34.39 32.57 36.00 9.51
Mar 33.44 31.43 34.96 10.10
Apr 35.77 33.96 37.65 9.80
May 35.12 33.98 38.41 11.52
Jun 36.13 35.14 37.78 7.00
Jul 36.22 34.83 39.65 12.17
Aug 34.83 33.37 36.29 8.06
Sep 34.79 31.70 37.08 14.52
Oct 35.91 32.55 38.07 14.49
Nov 31.91 29.42 34.55 14.85
Dec 32.60 29.54 35.10 15.82

Protagonist Therapeutics information and performance

Protagonist Therapeutics Address

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, US

Market Capitalization: 1 631 700 000 $

Market capitalization of the Protagonist Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of PTGX shares in the company outstanding by the market price of one share.

EBITDA: -92 675 000 $

EBITDA of Protagonist Therapeutics is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -1.39

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -1
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 15.58

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 21.56

Enterprise Value (EV) /Revenue

EV To EBITDA: -14.32

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 58275000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.